Monoclonal antibodies were the first to arrive, and earlier on, they were considered the first line of defense against the disease. Over the course of the pandemic, the U.S. Food and Drug ...

Monoclonal antibodies were once the star of COVID-19 outpatient treatments. Since they first became available in 2020 – even before the first vaccines – more than 3.5 million infusions of the ...

While common sense may suggest that antibodies that do not neutralize the SARS-CoV-2 virus are of little value, recent studies show they can still confer protection against infection. Monoclonal ...

Monoclonal antibodies (mAbs) are manufactured proteins that behave similarly to antibodies found naturally in the body. Researchers initially developed them for treating certain cancers but have ...

As the pandemic raged, monoclonal antibodies gained sudden prominence when these laboratory-made proteins were found to reduce the risk of hospitalization from COVID in vulnerable and ...

Monoclonal antibodies -- treatments developed by cloning a cell that makes an antibody -- could help provide an answer to the growing problem of antimicrobial resistance, say scientists.

Fc receptors for IgG (FcγRs) provide a key link between therapeutic antibodies and the cellular immune system and enable monoclonal antibodies to induce adaptive immune responses. Antibody ...

They are a type of medical treatment. Scientists make monoclonal antibodies, or mAbs, in a lab. They work like the natural antibodies your body makes to fight illness. They go out into your body ...